On November 7, 2023, the Federal Trade Commission (FTC) officially challenged more than 100 patents that brand name drug manufacturers have listed in the Food and Drug Administration’s (FDA) “Approved ...
The tension between regulatory compliance and antitrust exposure in Orange Book patent listings reached a dramatic inflection point this fall. In late October, Teva Pharmaceuticals agreed to pay $35 ...
Lawyers’ advice remains unchanged after the FTC targeted more than 100 Orange Book-listed patents, but they are preparing clients in case more patents are flagged The US Federal Trade Commission’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback